Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.

Vismodegib holds therapeutic potential in advanced basal cell carcinoma

10 Jan 2020

The Hedgehog pathway inhibitor vismodegib appears to be effective in the treatment of locally advanced periocular basal cell carcinoma (BCC), with adverse events (AEs) that are mostly manageable, as reported in a recent study.

The researchers reviewed the medical records of 21 patients (median age, 76 years; 76.2 percent male) with locally advanced and metastatic orbital (n=15) or periocular (n=6) BCC treated with vismodegib. Treatment went on for a median of 9 months.

Follow-up duration was 26 months overall and 17 months after cessation of treatment. Complete response was seen in 10 patients and partial response in another 10 patients, whereas disease remained stable in the remaining patient. Among the complete responders, five sustained a complete response at 16 months and three who stopped treatment experienced recurrence 8 months later.

Most treatment-related adverse reactions were low grade (grade 1 or 2). Frequently reported grade 1 or 2 complications were muscle spasm (76 percent), dysgeusia (57 percent), alopaecia (47 percent), weight loss (47 percent) and reduced appetite (19 percent). Hepatoxicity was the only documented high-grade (grade 3 or 4) adverse event (10 percent).

Treatment was withdrawn in eight patients due to side effects. There were five deaths overall, most of which were deemed unrelated to vismodegib therapy, except for one patient who died from potentially treatment-related sepsis (grade 5 adverse event).

The present data show that long periods of complete tumour regression can be achieved in some patients even after discontinuation of the medication, according to the researchers. However, the optimal treatment protocol and duration have yet to be established, highlighting a need for more prospective multicenter trials.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.